Exacerbation of warfarin-induced anticoagulation by hyperthyroidism

Area of Science:

• Endocrinology
• Pharmacology
• Hematology

Background:

• Hyperthyroidism can significantly alter drug metabolism and response.
• Warfarin is a commonly prescribed anticoagulant with a narrow therapeutic index.
• Potential interactions between thyroid hormones and warfarin pharmacokinetics are not fully understood.

Purpose of the Study:

• To highlight the critical interaction between warfarin and hyperthyroidism.
• To alert healthcare providers to the risk of severe coagulopathy in affected patients.
• To provide evidence-based recommendations for warfarin management in hyperthyroid individuals.

Main Methods:

• Presentation of two case reports detailing warfarin interaction in hyperthyroid patients.
• Comparison with a control group of hyperthyroid patients not on anticoagulant therapy.
• Analysis of warfarin serum levels, vitamin K therapy response, and clotting factor levels.

Main Results:

• Two hyperthyroid patients on warfarin developed severe coagulopathy.
• Patients exhibited resistance to vitamin K therapy for several days.
• One patient had warfarin serum levels five times the therapeutic range, suggesting altered absorption or protein binding.

Conclusions:

• Hyperthyroidism potentiates warfarin's anticoagulant effect through various mechanisms.
• Altered vitamin K-dependent clotting factor metabolism, warfarin metabolism, or decreased protein binding may contribute.
• Lower warfarin doses are recommended for hyperthyroid patients to prevent severe coagulopathy.